Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 8, 2026, the Board of Directors (the "Board") of Indaptus Therapeutics, Inc. (the "Company") increased its size from eight to nine members and appointed David Natan to fill the vacancy.

David Natan was appointed as a Class II director and will serve a term expiring at the 2026 annual meeting of stockholders, at which point he will stand for election by the shareholders. Mr. Natan is a nominee designated by Mr. David E. Lazar in exercise of Mr. Lazar's right to recommend three individuals to the Board under a securities purchase agreement dated December 22, 2025.

Mr. Natan currently serves as President and Chief Executive Officer of Natan & Associates, LLC, a consulting firm offering chief financial officer services to public and private companies in a variety of industries, both domestically and internationally, since 2007. From 2010 to May 2020, Mr. Natan served as Chief Executive Officer of ForceField Energy, Inc. (OTCMKTS: FNRG), a company focused on the solar industry and LED lighting products sourced from China. From February 2002 to November 2007, Mr. Natan served as Executive Vice President of Reporting and Chief Financial Officer of Pharma Net Development Group, Inc., a drug development services and clinical trials company, and, from June 1995 to February 2002, as Chief Financial Officer and Vice President of Global Technovations, Inc., a manufacturer and marketer of oil analysis instruments and speakers and speaker components. Prior to that, Mr. Natan served various roles in increasing responsibility with Deloitte & Touche LLP, a global accounting and consulting firm. Mr. Natan currently serves as a member of the Board of Directors and Chair of the Audit Committee of Sunshine Biopharma, Inc. (Nasdaq: SBFM), a pharmaceutical and nutritional supplement company, since February 2022. Additionally, since April 2024, Mr. Natan has served as a member of the Board of Directors and Audit Committee Chair of FIEE, Inc., a technology company specializing in SAAS solutions and Al software development, primarily in Hong Kong. Mr. Natan is a CPA (inactive), holds a B.A. in Economics from Boston University, and was appointed to Omicron Delta Epsilon, an international honor society in the field of Economics. Mr. Natan's extensive experience as an executive, his background in finance, and his exposure to public companies qualifies him to be on our Board.

Mr. Natan was appointed as a member of the Audit Committee replacing Mr. Avraham Ben-Tzvi whom the Company intends to engage as a paid consultant and who will continue to serve as a director on the Board. In connection with Mr. Natan's appointment to the Board and the Audit Committee, the Board has determined that Mr. Natan satisfies the definition of "independent director" and the heightened independence standards for service on the Board's Audit Committee under the NASDAQ listing standards.

Mr. Natan will participate in the Company's non-employee director compensation plan attached hereto as Exhibit 10.1 and incorporated herein by reference.